Bavarian Nordic (BAVA.CO)

Executive Summary

Bavarian Nordic is a leading Danish biotechnology company focused on developing and commercializing innovative vaccines, leveraging its proprietary viral vector platforms. The company has a strong portfolio of commercial vaccines, including IMVAMUNE (MVA-BN) for smallpox and mpox, and is actively advancing its pipeline in infectious diseases and oncology. Key near-term catalysts include the readout of Phase 2 data for MVA-BN in mpox (expected Q2 2026), potential U.S. government stockpiling orders for mpox vaccines, and the likely initiation of a Phase 3 trial for its chikungunya vaccine. With a market valuation of ~$14 billion and growing demand for travel and public health vaccines, Bavarian Nordic is well-positioned for sustained growth. The company's robust manufacturing capabilities and established commercial infrastructure support its leadership in the vaccine space. Near-term revenue visibility is supported by existing contracts and strong product sales.

Upcoming Catalysts (preview)

• Q2 2026Phase 2 MVA-BN mpox trial data readout80% success
• 2026U.S. government mpox vaccine stockpile contract50% success
• H2 2026Chikungunya vaccine Phase 3 trial initiation60% success